*僅供醫學專業人士閱讀參考

病理診斷與臨床決策如何“同頻共振”？“肺外神經內分泌癌病理前沿”專題系列給出答案

*以下內容僅供醫療衛生專業人士瀏覽。

醫學界腫瘤領域

參考文獻：

[1] NCCN Clinical Practice Guidelines in Oncology:Neuroendocrine and Adrenal Tumors, Version 1.2023,August 2,2023.

[2] Stumpo S, Formelli M G, Persano I, et al. Extrapulmonary neuroendocrine carcinomas: Current management and future perspectives[J]. Journal of Clinical Medicine, 2023, 12(24): 7715.

[3] Lokesh K N, Anand A, Lakshmaiah K C, et al. Clinical profile and treatment outcomes of metastatic neuroendocrine carcinoma: A single institution experience[J]. South Asian Journal of Cancer, 2018, 7(03): 207-209.

[4] Dasari A, Mehta K, Byers L A, et al. Comparative study of lung and extrapulmonary poorly differentiated neuroendocrine carcinomas: a SEER database analysis of 162,983 cases[J]. Cancer, 2018, 124(4): 807-815.

[5] Couvelard A, Cazes A, Cros J. Updates in histopathological classification and tissue biomarkers of digestive neuroendocrine neoplasms: What the clinician should know[J]. Best Practice & Research Clinical Endocrinology & Metabolism, 2023, 37(5): 101795.

[6] 中國臨床腫瘤學會指南工作委員會. 中國臨床腫瘤學會（CSCO）神經內分泌腫瘤診療指南 2024[M]. 北京 ：人民衛生出版社， 2024.

[7] Rindi G, Mete O, Uccella S, et al. Overview of the 2022 WHO classification of neuroendocrine neoplasms[J]. Endocrine pathology, 2022, 33(1): 115-154.

[8] Juhlin C C. The road ahead: a brief guide to navigating the 2022 WHO classification of endocrine and neuroendocrine tumours[J]. Journal of Clinical Pathology, 2025, 78(1): 1-10.

[9] Chen S, Sun L, Chen H, et al. Clinicopathological and genetic characteristics of gastric neuroendocrine tumour (NET) G3 and comparisons with neuroendocrine carcinoma and NET G2[J]. Histopathology, 2023, 83(5): 700-711.

[10] Sorbye H, Welin S, Langer S W, et al. Predictive and prognostic factors for treatment and survival in 305 patients with advanced gastrointestinal neuroendocrine carcinoma (WHO G3): the NORDIC NEC study[J]. Annals of oncology, 2013, 24(1): 152-160.

[11] Luong T V, Rejnmark L, Arveschoug A K, et al. Benefits of 11C-methionine PET/MRI and intraoperative fluorescence in treating hyperparathyroidism[J]. Endocrinology, Diabetes & Metabolism Case Reports, 2020, 2020(1).

[12] Hadoux J, Kanaan C, Durand A, et al. Prognostic factors of metastatic neuroendocrine carcinoma under first-line treatment with platinum etoposide with a focus on NEC score and Rb expression: Results from the multicentre RBNEC study of the Groupe d’Etude des Tumeurs Endocrines (GTE) and the ENDOCAN-RENATEN network[J]. European journal of cancer, 2021, 152: 100-115.

[13] Venizelos A, Elvebakken H, Perren A, et al. The molecular characteristics of high-grade gastroenteropancreatic neuroendocrine neoplasms[J]. Endocrine-related cancer, 2022, 29(1): 1-14.

[14] Yu S, Hornick J L, Gonzalez R S. An algorithmic approach utilizing CK7, TTF1, beta-catenin, CDX2, and SSTR2A can help differentiate between gastrointestinal and pulmonary neuroendocrine carcinomas[J]. Virchows Archiv, 2021, 479: 481-491.

審批編號：SC-CN-16729 有效日期：2026年5月28日

* 此文僅用于向醫學人士提供科學信息，不代表本平臺觀點